sobuzoxane has been researched along with B16 Melanoma in 2 studies
sobuzoxane: used in treatment of leukemia L1210
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sobuzoxane (MST-16) is an analogue of ICRF-159 which was once evaluated on the clinical efficacies in England." | 2.39 | [A novel antitumor agent, sobuzoxane (MST-16)]. ( Tsukagoshi, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsukagoshi, S | 2 |
| Narita, T | 1 |
| Yaguchi, S | 1 |
| Komatsu, T | 1 |
| Takase, M | 1 |
| Hoshino, A | 1 |
| Inaba, M | 1 |
1 review available for sobuzoxane and B16 Melanoma
| Article | Year |
|---|---|
[A novel antitumor agent, sobuzoxane (MST-16)].
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Leukemia, Experimental; | 1994 |
1 other study available for sobuzoxane and B16 Melanoma
| Article | Year |
|---|---|
Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Leukemia P388; Leukemia, Experimen | 1990 |